Apyx Medical Corporation provided earnings guidance for the full year 2022. For the year, the company expects Total revenue in the range of $50.0 million to $63.0 million, representing growth of 3% to 30% year-over-year, compared to total revenue of $48.5 million for the year ended December 31, 2021. Net loss attributable to stockholders in the range of $21.1 million to $12.1 million, compared to net loss attributable to stockholders of $15.2 million for the year ended December 31, 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.65 USD | +3.12% | +3.12% | -37.02% |
05-09 | Transcript : Apyx Medical Corporation, Q1 2024 Earnings Call, May 09, 2024 | |
05-09 | Stavros Vizirgianakis Enters into Letter Agreement with Apyx Medical | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.02% | 55.43M | |
-7.16% | 177B | |
-4.86% | 65.54B | |
-4.28% | 47.09B | |
+10.32% | 43.43B | |
+8.14% | 41.77B | |
+15.76% | 29.55B | |
+15.53% | 24.83B | |
-5.88% | 23.97B | |
-5.38% | 23.54B |
- Stock Market
- Equities
- APYX Stock
- News Apyx Medical Corporation
- Apyx Medical Corporation Provides Earnings Guidance for the Full Year 2022